Abstract
Recently the number of cancer case has been increasing. In addition, because of aging of the population and diversification of values among the people, less-invasive and high-QOL (quality of life) treatment for tumors has been needed. BNCT (Boron Neutron Capture Therapy) is based on the nuclear reaction of two essentially nontoxic species, 10B and thermal neutron. BNCT is effective and minimally invasive treatment. However BNCT is inefficient because atomic reactor is used for neutron source. In this study, we proposed to BNCT using an accelerator and new boron agents; HVJ (Hemagglutinating Virus of Japan) envelope (HVJ-E) and Boronated liposome (B-Liposome). HVJ-E is a nonviral vector using inactivated virus particle and it can deriver inclusions into cells via membrane-fusing activity. B-Liposome made of boronated phosphatide analogue can deliver the drug which is encapsulated into liposome with boron. We tried BNCT trail in vivo using an accelerator and new drugs. We used A549 cell line and OKTAVIAN which is 14 MeV neutron source by D-T reaction. In the result, these new boron agents realized the sufficient intracellular boron concentration and higher cytotoxicity reaction compared with a conventional boron compound (Sodium borocaptate: BSH). Therefore, we confirmed the possibility of BNCT using new drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
